KTTA - Pasithea Therapeutics Corp. Stock Price, Fair Value and News

$1.18-0.01 (-0.84%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

KTTA Price Action

Last 7 days

11.3%

Last 30 days

43.9%

Last 90 days

47.5%

Trailing 12 Months

-59.4%

KTTA RSI Chart

KTTA Valuation

Market Cap

8.8M

Price/Earnings (Trailing)

-0.65

Price/Sales (Trailing)

25.86

EV/EBITDA

-0.5

Price/Free Cashflow

-0.72

KTTA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KTTA Fundamentals

KTTA Revenue

Revenue (TTM)

423.2K

Rev. Growth (Yr)

-42.2%

Rev. Growth (Qtr)

-17.6%

KTTA Earnings

Earnings (TTM)

-13.5M

Earnings Growth (Yr)

-1.25%

Earnings Growth (Qtr)

18.26%

KTTA Profitability

EBT Margin

-3188.80%

Return on Equity

-110.55%

Return on Assets

-99%

Free Cashflow Yield

-139.56%

KTTA Investor Care

Shares Dilution (1Y)

487.76%

Diluted EPS (TTM)

-5.55

KTTA Alerts

3 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	698.5K	572.2K	515.5K	423.2K
2023	0	0	604.6K	763.9K
2022	0	0	0	486.6K
2021	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

CEO	Dr. Tiago Reis Marques M.D., Ph.D.
WEBSITE	pasithea.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	15

Pasithea Therapeutics Corp. Frequently Asked Questions

What is the ticker symbol for Pasithea Therapeutics Corp.? What does KTTA stand for in stocks?

KTTA is the stock ticker symbol of Pasithea Therapeutics Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pasithea Therapeutics Corp. (KTTA)?

As of Wed Dec 03 2025, market cap of Pasithea Therapeutics Corp. is 8.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KTTA stock?

You can check KTTA's fair value in chart for subscribers.

Is Pasithea Therapeutics Corp. a good stock to buy?

The fair value guage provides a quick view whether KTTA is over valued or under valued. Whether Pasithea Therapeutics Corp. is cheap or expensive depends on the assumptions which impact Pasithea Therapeutics Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KTTA.

What is Pasithea Therapeutics Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, KTTA's PE ratio (Price to Earnings) is -0.65 and Price to Sales (PS) ratio is 25.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KTTA PE ratio will change depending on the future growth rate expectations of investors.